Association between the low‑dose irinotecan regimen‑induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers

Moriya,Hiroyuki; Saito,Katsuhiko; Helsby,Nuala; Sugino,Shigekazu; Yamakage,Michiaki; Sawaguchi,Takeru; Takasaki,Masahiko; Kato,Hidenori; Kurosawa,Nahoko

doi:10.3892/ol.2014.2046

Association between the low‑dose irinotecan regimen‑induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers

Authors:
- Hiroyuki Moriya
- Katsuhiko Saito
- Nuala Helsby
- Shigekazu Sugino
- Michiaki Yamakage
- Takeru Sawaguchi
- Masahiko Takasaki
- Hidenori Kato
- Nahoko Kurosawa
View Affiliations

Affiliations: Department of Pharmacy, Hokkaido Pharmaceutical University School of Pharmacy, Otaru, Japan, Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan, Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan, Department of Gynecology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
Published online on: April 8, 2014 https://doi.org/10.3892/ol.2014.2046
Pages: 2035-2040

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The occurrence of severe neutropenia during treatment with irinotecan (CPT‑11) is associated with the *6 and *28 alleles of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). However, the correlation between these variants and the occurrence of severe neutropenia in a low‑dose CPT‑11 regimen for the treatment of gynecological cancers has not been extensively studied. There are also no studies regarding the association between the 421C>A mutation in ATP‑binding cassette sub-family G member 2 (ABCG2) and the occurrence of severe neutropenia in CPT‑11‑treated patients with gynecological cancers. The present study was designed to determine the factors associated with the occurrence of grade 4 neutropenia during chemotherapy for gynecological cancers with combinations of CPT‑11 and cisplatin or mitomycin C. In total, 44 patients with gynecological cancer were enrolled in the study. The association between the absolute neutrophil count (ANC) nadir values, the total dose of CPT‑11 and the genotypes of UGT1A1 or ABCG2 was studied. No correlation was observed between the ANC nadir values and the total dose of CPT‑11. The ANC nadir values in the UGT1A1*6/*28 and *6/*6 groups were significantly lower compared with those in the *1/*1 group (P<0.01). Univariate analysis showed no association between the occurrence of grade 4 neutropenia and the ABCG2 421C>A mutation. Subsequent to narrowing the factors by univariate analysis, multivariate logistic regression analysis only detected significant correlations between the occurrence of grade 4 neutropenia and the UGT1A1*6/*6 and *6/*28 groups (P=0.029; odds ratio, 6.90; 95% confidence interval, 1.22‑38.99). No associations were detected between the occurrence of grade 4 neutropenia and the heterozygous variant (*1/*6 or *1/*28) genotype, type of regimen or age. In conclusion, the UGT1A1*6/*28 and *6/*6 genotypes were found to be associated with the occurrence of severe neutropenia in the low‑dose CPT‑11 regimen for gynecological cancers. This finding indicates that the determination of UGT1A1 variants may be as useful in CPT‑11 chemotherapy for gynecological conditions as it is in colorectal and lung cancer patients treated with this drug.

View Figures

View References

1	Takano M, Kikuchi Y, Yaegashi N, et al: Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep. 16:1301–1306. 2006.PubMed/NCBI
2	Tanaka H, Kihira T, Nomura Y and Ishihara A: Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study. J Infect Chemother. 12:220–223. 2006. View Article : Google Scholar : PubMed/NCBI
3	Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:43–47. 2002.
4	Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 15:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI
5	Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A and Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 10:5151–5159. 2004. View Article : Google Scholar : PubMed/NCBI
6	Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 24:2237–2244. 2006. View Article : Google Scholar : PubMed/NCBI
7	Minami H, Sai K, Saeki M, et al: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A16 and 28. Pharmacogenet Genomics. 17:497–504. 2007.PubMed/NCBI
8	Jada SR, Lim R, Wong CI, et al: Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 98:1461–1467. 2007.
9	Hoskins JM, Goldberg RM, Qu P, Ibrahim JG and McLeod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 99:1290–1295. 2007.
10	Sai K, Saito Y, Sakamoto H, et al: Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett. 261:165–171. 2008.
11	Han JY, Lim HS, Park YH, Lee SY and Lee JS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 63:115–120. 2009. View Article : Google Scholar : PubMed/NCBI
12	Onoue M, Terada T, Kobayashi M, et al: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 14:136–142. 2009.
13	Takano M, Kato M, Yoshikawa T, et al: Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 76:315–321. 2009.
14	Takahara N, Nakai Y, Isayama H, et al: Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 71:85–92. 2013. View Article : Google Scholar
15	Stewart CF, Panetta JC, O’Shaughnessy MA, et al: UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 25:2594–2600. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sugiyama T, Hirose T, Kusumoto S, et al: The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Oncol Res. 18:337–342. 2010.
17	Guillemette C: Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3:136–158. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kaniwa N, Kurose K, Jinno H, et al: Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos. 33:458–465. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kurose K, Sugiyama E and Saito Y: Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 27:9–54. 2012. View Article : Google Scholar
20	Imai Y, Nakane M, Kage K, et al: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther. 1:611–616. 2002.PubMed/NCBI
21	Han JY, Lim HS, Yoo YK, et al: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 110:138–147. 2007. View Article : Google Scholar : PubMed/NCBI
22	National Cancer Institute. Common Terminology Criteria for Adverse Events v 3.0 (CTCAE). Cancer Therapy Evaluation Program. 2006.
23	Moriya H, Saito K, Helsby N, et al: The association between heterozygosity for UGT1A16, UGT1A128, and variation in the serum total-bilirubin level in healthy young Japanese adults. Genet Test Mol Biomarkers. 17:464–469. 2013.
24	Gao J, Zhou J, Li Y, Lu M, Jia R and Shen L: UGT1A16/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol. 30:6042013.
25	Comella P, Farris A, Lorusso V, et al: Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. Br J Cancer. 89:992–996. 2003. View Article : Google Scholar
26	Chau I, Norman AR, Cunningham D, et al: Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer. 91:1453–1458. 2004. View Article : Google Scholar
27	Souglakos J, Pallis A, Kakolyris S, et al: Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology. 69:384–390. 2005. View Article : Google Scholar : PubMed/NCBI
28	Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 15:251–260. 1997.PubMed/NCBI
29	Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J and Mishima H: Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol. 41:477–482. 2011.
30	Sunakawa Y, Ichikawa W, Fujita K, et al: UGT1A11/28 and 1/6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 68:279–284. 2011.
31	Cha PC, Mushiroda T, Zembutsu H, et al: Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet. 54:572–580. 2009. View Article : Google Scholar : PubMed/NCBI
32	Sai K, Saito Y, Maekawa K, et al: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 66:95–105. 2010. View Article : Google Scholar
33	Cecchin E, Innocenti F, D’Andrea M, et al: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 27:2457–2465. 2009. View Article : Google Scholar
34	Lévesque E, Bélanger AS, Harvey M, et al: Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Ther. 345:95–101. 2013.
35	Glimelius B, Garmo H, Berglund A, et al: Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
36	van der Bol JM, Mathijssen RH, Loos WJ, et al: Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol. 25:2719–2726. 2007.PubMed/NCBI